Until recently, we were focused on the research and development of novel therapeutics for neurodegenerative diseases, such as Niemann Pick disease type C (NPC).
In May 2022, substantially all our assets and business activities, including those relating to the development and approval of arimoclomol, were sold to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm, Inc.
Company announcement Orphazyme A/S No. 36/2022 www.orphazyme.com Company Registration No. 32266355 C o penhagen, Denmark, September 26, 2022 – Orphazyme A/S (ORPHA.CO) (the “Company”) today announces its Interim Report First Half 2021 for the period January 1 – June 30, 2022.
Orphazyme A/S Company announcement No. 35/2022 www.orphazyme.com Company Registration No. 32266355 C o penhagen, Denmark, September 2 5 , 2022 – Orphazyme A/S (ORPHA.CO) (the “Company”) has decided to adjust its outlook for 2022, as published on June 7, 2022.
Company announcement Orphazyme A/S No. 34/2022 www.orphazyme.com Company Registration No. 32266355 C o penhagen, Denmark, September 19 , 2022 – Orphazyme A/S (ORPHA.CO) (the “Company”) announces an update to the Company’s financial calendar in regard to the publication of the Company’s Interim
